Galvecta Plus (metformin + vildagliptin): Uses, Dosage & Side Effects

What it's for (Indications)

Metformin + Vildagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
This combination therapy is particularly suitable for patients whose blood glucose levels are inadequately controlled by metformin monotherapy alone, or for those who are already being treated with separate tablets of vildagliptin and metformin.
It addresses the multifaceted pathophysiology of type 2 diabetes by utilizing two complementary mechanisms of action, offering comprehensive glucose-lowering effects to achieve target HbA1c levels.
The initiation and continuation of treatment should always be part of a broader diabetes management plan that includes robust lifestyle modifications, focusing on diet, regular physical activity, and weight management as appropriate for the individual patient's health profile and goals.
This combination aims to provide a more effective approach to glycemic management compared to monotherapy when either agent alone is insufficient.

Dosage Information

Type	Guideline
Standard	The dosage of Metformin + Vildagliptin must be carefully individualized based on the patient’s current glycemic control, current regimen of metformin or vildagliptin (if applicable), efficacy, and tolerability, while ensuring that the maximum recommended daily dose of 100 mg of vildagliptin and 2000 mg of metformin hydrochloride is not exceeded. This fixed-dose combination is typically administered orally twice daily with meals to mitigate gastrointestinal side effects frequently associated with the metformin component, thereby enhancing patient compliance. Common available strengths include 50 mg vildagliptin combined with 500 mg, 850 mg, or 1000 mg of metformin hydrochloride. Patients previously on monotherapy with either agent should transition to the combination at an equivalent therapeutic dose, with gradual titration if necessary. Renal function must be meticulously assessed prior to initiation and periodically thereafter due to the risk of metformin accumulation in patients with impaired renal function, necessitating dose adjustments or contraindication based on estimated glomerular filtration rate (eGFR).

Type

Guideline

Standard

The dosage of Metformin + Vildagliptin must be carefully individualized based on the patient’s current glycemic control, current regimen of metformin or vildagliptin (if applicable), efficacy, and tolerability, while ensuring that the maximum recommended daily dose of 100 mg of vildagliptin and 2000 mg of metformin hydrochloride is not exceeded. This fixed-dose combination is typically administered orally twice daily with meals to mitigate gastrointestinal side effects frequently associated with the metformin component, thereby enhancing patient compliance. Common available strengths include 50 mg vildagliptin combined with 500 mg, 850 mg, or 1000 mg of metformin hydrochloride. Patients previously on monotherapy with either agent should transition to the combination at an equivalent therapeutic dose, with gradual titration if necessary. Renal function must be meticulously assessed prior to initiation and periodically thereafter due to the risk of metformin accumulation in patients with impaired renal function, necessitating dose adjustments or contraindication based on estimated glomerular filtration rate (eGFR).

Safety & Warnings

Common Side Effects

Patients receiving Metformin + Vildagliptin may experience a range of side effects, primarily related to the individual components.
Common gastrointestinal disturbances, such as nausea, vomiting, diarrhea, abdominal pain, and loss of appetite, are frequently associated with metformin, particularly during treatment initiation or dose escalation.
Other commonly reported adverse reactions include headache, dizziness, tremor, nasopharyngitis, and upper respiratory tract infection, often linked to the vildagliptin component.
More serious, albeit rare, side effects include lactic acidosis (a metformin-associated risk, discussed further in the Black Box Warning), acute pancreatitis (a vildagliptin-associated risk), and severe arthralgia, which can be debilitating.
Hypoglycemia can occur, especially when this combination is co-administered with sulfonylureas or insulin, or in situations of caloric restriction, intense physical exercise, or excessive alcohol intake.
Hepatic enzyme elevations, although usually asymptomatic and reversible, have also been observed with vildagliptin and warrant periodic monitoring of liver function tests.
Skin reactions, such as bullous pemphigoid, have been reported post-marketing.

Serious Warnings

Black Box Warning: **WARNING: Lactic Acidosis** Metformin, a component of Metformin + Vildagliptin, carries a Black Box Warning for the risk of lactic acidosis. Lactic acidosis is a rare, but serious and potentially fatal, metabolic complication that can occur due to metformin accumulation during treatment with metformin-containing products. The incidence of metformin-associated lactic acidosis (MALA) is approximately 0.03 cases per 1,000 patient-years, with a fatality rate of approximately 50%. The onset of lactic acidosis is often subtle, associated with non-specific symptoms such as malaise, myalgia, respiratory distress, increasing somnolence, and non-specific abdominal distress. More severe acidosis can lead to hypothermia, hypotension, and resistant bradyarrhythmias. Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (i.e., ketonuria and ketonemia) and with an elevated anion gap. Risk factors for metformin-associated lactic acidosis include significant renal impairment (eGFR < 30 mL/min/1.73m²), concomitant use of drugs that can impair renal function (e.g., NSAIDs, ACE inhibitors, ARBs, diuretics), conditions causing tissue hypoperfusion and hypoxemia (e.g., acute congestive heart failure, sepsis, acute myocardial infarction), excessive alcohol intake, hepatic impairment, and dehydration. Therefore, renal function should be assessed prior to initiation of therapy and periodically thereafter. Metformin should be temporarily withheld in conditions predisposing to hypoxemia or renal impairment, such as acute decompensated heart failure. If lactic acidosis is suspected, Metformin + Vildagliptin should be discontinued immediately, and supportive measures, including prompt hospitalization, initiated. Hemodialysis is strongly recommended for rapid correction of acidosis and effective removal of accumulated metformin from the body, as metformin is dialyzable with a clearance up to 170 mL/min under good hemodynamic conditions. Healthcare professionals should thoroughly assess patient risk factors before and during therapy with Metformin + Vildagliptin to minimize the risk of this severe complication.
Several critical warnings are associated with Metformin + Vildagliptin.
The most significant is the risk of lactic acidosis, a rare but severe metabolic complication primarily associated with metformin, which can be fatal.
Patients and healthcare providers must be aware of its symptoms and risk factors, including renal impairment, acute heart failure, and excessive alcohol intake.
Acute pancreatitis has been reported with vildagliptin; patients experiencing persistent severe abdominal pain should discontinue treatment and be thoroughly evaluated.
Hypoglycemia risk significantly increases when this combination is co-administered with insulin or sulfonylureas, necessitating dose adjustments of the concomitant agents.
Renal function must be meticulously assessed before initiating treatment and at least annually thereafter, as metformin is substantially excreted by the kidney, and its accumulation increases lactic acidosis risk.
Severe hepatic impairment is a contraindication, and liver enzyme monitoring is recommended with vildagliptin use.
Other warnings include potential for severe and disabling arthralgia, requiring discontinuation if pain persists, and the risk of vitamin B12 deficiency with long-term metformin use.
Cases of bullous pemphigoid, requiring discontinuation, have also been reported.

How it Works (Mechanism of Action)

Metformin + Vildagliptin combines two distinct antihyperglycemic agents with complementary mechanisms to enhance glycemic control in adults with type 2 diabetes. Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that selectively prevents the rapid enzymatic degradation of incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This inhibition leads to increased fasting and postprandial concentrations of active incretins, which in turn augment glucose-dependent insulin secretion from pancreatic beta cells and suppress glucagon secretion from pancreatic alpha cells, thereby reducing hepatic glucose production. Metformin, a biguanide, primarily reduces hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis in the liver. It also decreases intestinal absorption of glucose and improves insulin sensitivity by enhancing peripheral glucose uptake and utilization in muscle and adipose tissues. The synergistic effect of these two agents, by addressing both insulin secretion and insulin resistance pathways, leads to improved glycemic control with a low risk of hypoglycemia when used alone or in combination without other insulin secretagogues, and without causing weight gain, which is often a concern with other antidiabetic therapies.